Van Rensburg C E, Van Staden A M, Anderson R
Department of Immunology, Faculty of Medicine, University of Pretoria, Republic of South Africa.
Cancer Res. 1993 Jan 15;53(2):318-23.
Clofazimine, a riminophenazine antimicrobial agent, and its analogue B669 were investigated for their effects on FaDu cells, a human squamous carcinoma cell line. These agents, at concentrations within the therapeutic range (0.25-2 micrograms/ml), caused a dose-dependent tumor cell cytotoxicosis which was greatly enhanced in the presence of human neutrophils. The neutrophil-mediated increment in tumoricidal activity, but not the direct antitumor effects of the drugs per se, was inhibited by catalase. The effects of these drugs on three more cell carcinoma lines as well as on two primary cultures and a noncarcinoma cell line were also investigated and compared with the activity of the standard antitumor chemotherapeutic agents bleomycin, cisplatin, and methotrexate. All seven cultures were sensitive to clofazimine and B669 compared to six that were sensitive to cisplatin, three that were sensitive to bleomycin, and one that was sensitive to methotrexate. The treatment of FaDu cells with clofazimine and B669 was associated with enhanced activity of phospholipase A2, as evidenced by increased release of radiolabeled arachidonate and lysophosphatidylcholine from membrane phospholipids. Inhibitors of arachidonic acid metabolism, protein kinase C inhibitors, as well as water and lipid soluble antioxidants failed to protect the cells against the cytotoxic activity of clofazimine and B669. However, alpha-tocopherol, a lysophospholipid-complexing agent, completely blocked the antiproliferative effects of the riminophenazines and also protected the cells against the direct cytotoxic effect of lysophosphatidylcholine, while the lysophospholipid-neutralizing enzyme lysophospholipase protected against the riminophenazines. These observations demonstrate that the tumoricidal properties of clofazimine and B669 are probably due to increases in the lysophospholipid content of cell membranes.
氯法齐明是一种二氨基吩嗪类抗菌剂,对其类似物B669对人鳞状癌细胞系FaDu细胞的作用进行了研究。这些药物在治疗范围内的浓度(0.25 - 2微克/毫升)会引起剂量依赖性的肿瘤细胞细胞毒性,在人中性粒细胞存在的情况下这种毒性会大大增强。过氧化氢酶可抑制中性粒细胞介导的杀肿瘤活性增强,但不影响药物本身的直接抗肿瘤作用。还研究了这些药物对另外三种癌细胞系以及两种原代培养物和一种非癌细胞系的作用,并与标准抗肿瘤化疗药物博来霉素、顺铂和甲氨蝶呤的活性进行了比较。与六种对顺铂敏感、三种对博来霉素敏感和一种对甲氨蝶呤敏感的培养物相比,所有七种培养物对氯法齐明和B669均敏感。用氯法齐明和B669处理FaDu细胞与磷脂酶A2活性增强有关,这可通过膜磷脂中放射性标记的花生四烯酸和溶血磷脂酰胆碱释放增加来证明。花生四烯酸代谢抑制剂、蛋白激酶C抑制剂以及水溶性和脂溶性抗氧化剂均不能保护细胞免受氯法齐明和B669的细胞毒性作用。然而,α-生育酚是一种溶血磷脂络合剂,它完全阻断了二氨基吩嗪类化合物的抗增殖作用,还保护细胞免受溶血磷脂酰胆碱的直接细胞毒性作用,而溶血磷脂中和酶溶血磷脂酶则可保护细胞免受二氨基吩嗪类化合物的作用。这些观察结果表明,氯法齐明和B669的杀肿瘤特性可能是由于细胞膜中溶血磷脂含量增加所致。